FDA Clears Takeda's Orzeyful for 120,000 U.S. Narcolepsy Patients as First Orexin-Mimicking Drug
Updated
Updated · Smithsonian Magazine · Aug 18
FDA Clears Takeda's Orzeyful for 120,000 U.S. Narcolepsy Patients as First Orexin-Mimicking Drug
3 articles · Updated · Smithsonian Magazine · Aug 18
Summary
Orzeyful won FDA approval in early August as the first medicine to target narcolepsy type 1’s underlying biology rather than just easing symptoms.
Takeda’s twice-daily oral drug mimics orexin—the chemical lost in many type 1 patients—aiming to restore wakefulness, nighttime sleep and muscle-tone control.
In two late-stage trials involving 273 adults over 12 weeks, treated patients stayed awake longer, slept better at night and had fewer cataplexy episodes than placebo, with no serious treatment-related adverse events.
The approval could benefit roughly 120,000 U.S. patients with narcolepsy type 1, though experts say orexin loss does not explain every case and future care may still require combination therapies.
Takeda and outside researchers say the success of Orzeyful may also broaden interest in orexin-based drugs for other disorders linked to low orexin levels, including ADHD and Parkinson’s disease.